RT Journal Article SR Electronic T1 Enhancement of μ Opioid Antinociception by Oral Δ9-Tetrahydrocannabinol: Dose-Response Analysis and Receptor Identification JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 859 OP 867 VO 289 IS 2 A1 Diana L. Cichewicz A1 Zachary L. Martin A1 Forrest L. Smith A1 Sandra P. Welch YR 1999 UL http://jpet.aspetjournals.org/content/289/2/859.abstract AB The antinociceptive effects of various μ opioids given p.o. alone and in combination with Δ-9-tetrahydrocannabinol (Δ9-THC) were evaluated using the tail-flick test. Morphine preceded by Δ9-THC treatment (20 mg/kg) was significantly more potent than morphine alone, with an ED50 shift from 28.8 to 13.1 mg/kg. Codeine showed the greatest shift in ED50 value when administered after Δ9-THC (139.9 to 5.9 mg/kg). The dose-response curves for oxymorphone and hydromorphone were shifted 5- and 12.6-fold, respectively. Methadone was enhanced 4-fold, whereas its derivative, l-α-acetylmethadol, was enhanced 3-fold. The potency ratios after pretreatment with Δ9-THC for heroin and meperidine indicated significant enhancement (4.1 and 8.9, respectively). Pentazocine did not show a parallel shift in its dose-response curve with Δ9-THC. Naloxone administration (1 mg/kg s.c.) completely blocked the antinociceptive effects of morphine p.o. and codeine p.o. The Δ9-THC-induced enhancement of morphine and codeine was also significantly decreased by naloxone administration. Naltrindole (2 mg/kg s.c.) did not affect morphine or codeine antinociception but did block the enhancement of these two opioids by Δ9-THC. No effect was seen when nor-binaltorphimine was administered 2 mg/kg s.c. before morphine or codeine. Furthermore, the enhancements of morphine and codeine were not blocked by nor-binaltorphimine. We find that many μ opioids are enhanced by an inactive dose of Δ9-THC p.o. The exact nature of this enhancement is unknown. We show evidence of involvement of μ and possibly δ opioid receptors as a portion of this signaling pathway that leads to a decrease in pain perception. The American Society for Pharmacology and Experimental Therapeutics